Tenaya Therapeutics, Inc.
Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering and developing therapies for heart disease. Its candidates include TN-201, an AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy; TN-401, an AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy; and TN-301, a small-molecule HDAC6 inhibitor studied for heart failure with preserved ejection fraction and other conditions. The company also has earlier-stage programs using approaches including gene editing, gene silencing and cardiac regeneration. Its capabilities include target discovery and validation, genetic medicine design, and manufacturing. Tenaya expects to develop, manufacture and commercialize at least some therapies for rare conditions itself, while seeking partners for candidates aimed at more prevalent diseases. Its March 2026 research collaboration with Alnylam covers cardiovascular gene targets, with Alnylam reimbursing specified research costs and holding rights to develop and commercialize products directed to collaboration targets. Tenaya is headquartered in South San Francisco, California.
No enriched coverage for $TNYA in the last 7 days.
No SEC Form 4 filings for $TNYA in the last 30 days.
See all $TNYA insider activity →Tenaya Therapeutics reported Q3 GAAP EPS of -$0.08, beating estimates by $0.02, with revenue of $1.7M, exceeding expectations by $0.9M. The company recently presented at investment conferences.
Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
Recent TNYA coverage spans earnings, technology and financial news.
Earnings beat on both EPS and revenue may lift sentiment for the micro‑cap biotech.
New financial results and regulatory milestone could boost investor confidence.
RMAT status accelerates development timeline and may attract partnership interest.
Q4 regulatory update and durability plans for TN-401 are the near-term catalysts, with TN-301 Phase 2 plans as the secondary timeline.
Positive interim gene-therapy readouts and a $10M Alnylam upfront extend runway, but near-term valuation remains highly dependent on late-stage pivotal trial alignment.
AlphAI scores every news story that mentions TNYA with an AI model for sentiment and relevance, and aggregates insider trades from Tenaya Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tenaya Therapeutics reported Q3 GAAP EPS of -$0.08, beating estimates by $0.02, with revenue of $1.7M, exceeding expectations by $0.9M. The company recently presented at investment conferences.
Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
Tenaya Therapeutics (NASDAQ:TNYA) said it plans Q4 updates for gene therapy TN-401 in PKP2-associated ARVC, with early data showing ~60% to 67% PVC reductions across patients (up to 52 weeks). It also reported Phase 1 results for TN-301 (72 patients) and Phase 2-enabling work. Tenaya had ~$78M cash and a $10M upfront Alnylam deal.
Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional
Tenaya Therapeutics (NASDAQ: TNYA) said it granted inducement stock options to its new CFO Eric Hyllengren for 1,650,000 shares and options totaling 187,200 shares to two new non-executive employees. The options’ exercise price is $0.8365, matching July 13, 2026’s close, with a 10-year term and 4-year vesting.
Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. 8-K 0001858848 false 0001858848 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,
Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001858848 false 0001858848 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,
Tenaya Therapeutics reported interim MyPEAK-1 Phase 1b/2 data for TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic cardiomyopathy. As of a May 2026 cutoff, six evaluable patients showed improvements in echocardiographic hypertrophy and symptom measures; three improved exercise capacity. Company said benefits were sustained up to two years in Cohort 1 and earlier in Cohort 2. PRIME and FDA rare disease processes apply.
Tenaya Therapeutics CEO Ali Faraz sold 3,390 shares of common stock at $0.7934 per share on May 18, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. After this transaction, Faraz directly holds 440,014 shares, which includes 321,581 shares that will be issued upon future RSU vesting. This sale is identified as being for tax purposes rather than a reduction in long-term holdings.
